BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3896044)

  • 1. Blood flow properties and walking performance in chronic arterial occlusive disease.
    Angelkort B; Spürk P; Habbaba A; Mähder M
    Angiology; 1985 May; 36(5):285-92. PubMed ID: 3896044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease.
    Perego MA; Sergio G; Artale F; Giunti P; Danese C
    Curr Med Res Opin; 1986; 10(2):135-8. PubMed ID: 3709212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypervolumetric hemodilution with HES 100/0.5 10% in patients with peripheral arterial occlusive disease (Fontaine, stage II): an open clinical and pharmacological phase IV study.
    Koscielny J; Latza R; Pruss A; Kiesewetter H; Jung F; Meier C; Schimetta W
    Clin Hemorheol Microcirc; 2000; 22(1):53-65. PubMed ID: 10711822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of chronic arterial occlusive disease. Clinical study with a new galenic preparation of Pentoxifyllin (Trental 400) (author's transl)].
    Angelkort B; Doppelfeld E
    Med Klin; 1978 May; 73(21):791-7. PubMed ID: 651768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
    Chopra HK; Chopra KL; Aggarwal KK; Parashar SK
    J Med; 1988; 19(2):89-107. PubMed ID: 3049876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hemorrheological factors in the developmental stages of peripheral arterial occlusive diseases].
    Artale F; Sergio G; Cramarossa L; Giunti P; Francisci A; Perego MA
    Ric Clin Lab; 1983; 13 Suppl 3():411-5. PubMed ID: 6673022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyper- or isovolemic hemodilution in patients with stage II peripheral arterial occlusive disease].
    Kiesewetter H; Jung F; Blume J; Spitzer S; Birk A
    Acta Med Austriaca; 1991; 18 Suppl 1():23-7. PubMed ID: 1719729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease.
    Di Perri T; Carandente O; Vittoria A; Guerrini M; Messa GL
    Angiology; 1984 Jul; 35(7):427-35. PubMed ID: 6540539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Iso- and hypervolemic hemodilution with hydroxyethyl starch (HES 200/.05 10%) in patients with II b peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Spitzer S; Gerhards M; Waldhausen P; Wenzel E
    Wien Med Wochenschr; 1989 Sep; 139(17):396-401. PubMed ID: 2480029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs.
    Strano A; Davi G; Avellone G; Novo S; Pinto A
    Angiology; 1984 Jul; 35(7):459-66. PubMed ID: 6380350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator-nylidrin.
    Accetto B
    Am Heart J; 1982 May; 103(5):864-9. PubMed ID: 7041579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis.
    Poggesi L; Scarti L; Boddi M; Masotti G; Serneri GG
    Angiology; 1985 Sep; 36(9):628-37. PubMed ID: 3901827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Red cell flexibility and platelet aggregation in patients with chronic obstructive vascular disease (COAD) and study of therapeutic approaches.
    Ambrus JL; Ambrus CM; Taheri SA; Gastpar H; Reddington MM; Taheri P; Kahn EA; Schattman GL; Dean LS; Moore RH
    Angiology; 1984 Jul; 35(7):418-26. PubMed ID: 6540538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects.
    Reilly DT; Quinton DN; Barrie WW
    N Z Med J; 1987 Jul; 100(828):445-7. PubMed ID: 3330188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hemodilution in patients with multiple morbidity and peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Spitzer S; Bach R; Birk A; Schieffer H; Wenzel E
    Schweiz Med Wochenschr; 1989 Dec; 119(51):1862-7. PubMed ID: 2481883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of buflomedil in a group of patients with chronic peripheral arterial diseases. Clinical and hemorheological evaluation.
    Mozzi E; Chiurazzi D; Spinola A; Annoni F; Germiniani R
    J Int Med Res; 1985; 13(6):317-21. PubMed ID: 4076530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Blood rheology in chronic arterial occlusive disease as influenced by vasodilators (author's transl)].
    Störmer B; Kleinschmidt F; Loose D; Kremer K
    Dtsch Med Wochenschr; 1978 Apr; 103(16):694-8. PubMed ID: 639718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheological and anticoagulant therapy of patients with chronic peripheral occlusive arterial disease (COAD).
    Deutschinoff A; Grozdinsky L
    Angiology; 1987 May; 38(5):351-8. PubMed ID: 3296861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Blood rheological changes and their clinical significance in chronic arterial obstructive disease].
    Sternitzky R; Seige K
    Z Gesamte Inn Med; 1983 Jan; 38(1):1-7. PubMed ID: 6342278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blood rheology in peripheral occlusive disease. Effects of hemodilution and pentoxifylline].
    Angelkort B
    Wien Med Wochenschr; 1986; 136 Spec No():29-35. PubMed ID: 3548089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.